Clinical efficacy, safety and tolerance of the Kerawort (imiquimod) cream used for treatment of anogenital warts
Goal of the study. To assess the efficacy and safety of Kerawort (Imiquimod, 5% cream for topical administration) vs. placebo used for treatment of anogenital warts. Methods and materials. The single-blind comparative placebo-controlled study involved 90 patients (44 female and 46 male) with anogeni...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
State Scientific Center of Dermatovenereology and Cosmetology
2017-08-01
|
| Series: | Vestnik Dermatologii i Venerologii |
| Subjects: | |
| Online Access: | https://www.vestnikdv.ru/jour/article/view/115 |
| _version_ | 1827838290809585664 |
|---|---|
| author | M. R. Rakhmatulina A. A. Kubanov A. V. Samtsov A. V. Sukharev O. I. Bondar A. V. Semenenko |
| author_facet | M. R. Rakhmatulina A. A. Kubanov A. V. Samtsov A. V. Sukharev O. I. Bondar A. V. Semenenko |
| author_sort | M. R. Rakhmatulina |
| collection | DOAJ |
| description | Goal of the study. To assess the efficacy and safety of Kerawort (Imiquimod, 5% cream for topical administration) vs. placebo used for treatment of anogenital warts. Methods and materials. The single-blind comparative placebo-controlled study involved 90 patients (44 female and 46 male) with anogenital warts. The patients were randomized into two groups: the main group (n = 45) receiving treatment with Kerawort (Imiquimod, 5% cream) and the control group (n = 45) receiving placebo. The diagnosis was confirmed by the identification of human papillomavirus by the polymerase chain reaction method. The patients received treatment three times a week until clinical signs disappeared but for not more than 16 weeks. Results. In 95.6% of patients from the main group and 8.9% of patients from the control group, anogenital warts disappeared completely or the quantity/area of pathological eruptions reduced at least by 70% as compared to the baseline. No relapses occurred during the treatment and follow-up period (28 days after the completion of treatment) in patients from the main group. An increase in the size and/or area of anogenital warts and/or development of new eruptions on the skin and mucous membrane of the genitals were recorded in 11.1% of patients from the control group. No serious adverse events were revealed during the study. Conclusion. Higher efficacy (р < 0.0000001) and comparable safety of Kerawort (Imiquimod, 5% cream for topical administration) used for treatment of anogenital warts vs. placebo were reliably established. |
| first_indexed | 2024-03-12T07:03:30Z |
| format | Article |
| id | doaj.art-c3052a5d08f740489da1c632fdae113d |
| institution | Directory Open Access Journal |
| issn | 0042-4609 2313-6294 |
| language | English |
| last_indexed | 2024-03-12T07:03:30Z |
| publishDate | 2017-08-01 |
| publisher | State Scientific Center of Dermatovenereology and Cosmetology |
| record_format | Article |
| series | Vestnik Dermatologii i Venerologii |
| spelling | doaj.art-c3052a5d08f740489da1c632fdae113d2023-09-02T23:38:33ZengState Scientific Center of Dermatovenereology and CosmetologyVestnik Dermatologii i Venerologii0042-46092313-62942017-08-010112913410.25208/0042-4609-2015-0-1-129-134114Clinical efficacy, safety and tolerance of the Kerawort (imiquimod) cream used for treatment of anogenital wartsM. R. Rakhmatulina0A. A. Kubanov1A. V. Samtsov2A. V. Sukharev3O. I. Bondar4A. V. Semenenko5State Research Center of Dermatovenereology and Cosmetology, Ministry of Healthcare of the Russian FederationState Research Center of Dermatovenereology and Cosmetology, Ministry of Healthcare of the Russian FederationMilitary Medical Academy named after S.M. Kirov Ministry of Defense of the Russian FederationMilitary Medical Academy named after S.M. Kirov Ministry of Defense of the Russian FederationMilitary Medical Academy named after S.M. Kirov Ministry of Defense of the Russian FederationRussian Medical Academy of Postgraduate Studies, Ministry of Health of the Russian FederationGoal of the study. To assess the efficacy and safety of Kerawort (Imiquimod, 5% cream for topical administration) vs. placebo used for treatment of anogenital warts. Methods and materials. The single-blind comparative placebo-controlled study involved 90 patients (44 female and 46 male) with anogenital warts. The patients were randomized into two groups: the main group (n = 45) receiving treatment with Kerawort (Imiquimod, 5% cream) and the control group (n = 45) receiving placebo. The diagnosis was confirmed by the identification of human papillomavirus by the polymerase chain reaction method. The patients received treatment three times a week until clinical signs disappeared but for not more than 16 weeks. Results. In 95.6% of patients from the main group and 8.9% of patients from the control group, anogenital warts disappeared completely or the quantity/area of pathological eruptions reduced at least by 70% as compared to the baseline. No relapses occurred during the treatment and follow-up period (28 days after the completion of treatment) in patients from the main group. An increase in the size and/or area of anogenital warts and/or development of new eruptions on the skin and mucous membrane of the genitals were recorded in 11.1% of patients from the control group. No serious adverse events were revealed during the study. Conclusion. Higher efficacy (р < 0.0000001) and comparable safety of Kerawort (Imiquimod, 5% cream for topical administration) used for treatment of anogenital warts vs. placebo were reliably established.https://www.vestnikdv.ru/jour/article/view/115аногенитальные бородавкивирус папилломы человекаимихимодкеравортanogenital wartshuman papillomavirusimiquimodkerawort |
| spellingShingle | M. R. Rakhmatulina A. A. Kubanov A. V. Samtsov A. V. Sukharev O. I. Bondar A. V. Semenenko Clinical efficacy, safety and tolerance of the Kerawort (imiquimod) cream used for treatment of anogenital warts Vestnik Dermatologii i Venerologii аногенитальные бородавки вирус папилломы человека имихимод кераворт anogenital warts human papillomavirus imiquimod kerawort |
| title | Clinical efficacy, safety and tolerance of the Kerawort (imiquimod) cream used for treatment of anogenital warts |
| title_full | Clinical efficacy, safety and tolerance of the Kerawort (imiquimod) cream used for treatment of anogenital warts |
| title_fullStr | Clinical efficacy, safety and tolerance of the Kerawort (imiquimod) cream used for treatment of anogenital warts |
| title_full_unstemmed | Clinical efficacy, safety and tolerance of the Kerawort (imiquimod) cream used for treatment of anogenital warts |
| title_short | Clinical efficacy, safety and tolerance of the Kerawort (imiquimod) cream used for treatment of anogenital warts |
| title_sort | clinical efficacy safety and tolerance of the kerawort imiquimod cream used for treatment of anogenital warts |
| topic | аногенитальные бородавки вирус папилломы человека имихимод кераворт anogenital warts human papillomavirus imiquimod kerawort |
| url | https://www.vestnikdv.ru/jour/article/view/115 |
| work_keys_str_mv | AT mrrakhmatulina clinicalefficacysafetyandtoleranceofthekerawortimiquimodcreamusedfortreatmentofanogenitalwarts AT aakubanov clinicalefficacysafetyandtoleranceofthekerawortimiquimodcreamusedfortreatmentofanogenitalwarts AT avsamtsov clinicalefficacysafetyandtoleranceofthekerawortimiquimodcreamusedfortreatmentofanogenitalwarts AT avsukharev clinicalefficacysafetyandtoleranceofthekerawortimiquimodcreamusedfortreatmentofanogenitalwarts AT oibondar clinicalefficacysafetyandtoleranceofthekerawortimiquimodcreamusedfortreatmentofanogenitalwarts AT avsemenenko clinicalefficacysafetyandtoleranceofthekerawortimiquimodcreamusedfortreatmentofanogenitalwarts |